Please select the option that best describes you:
For an otherwise healthy individual, what would be your front line choice for de novo Richter’s transformation?
Pathology is clear this is not a concurrent DLBCL and is indeed transformed CLL
Answer from: Medical Oncologist at Academic Institution
The management of de novo transformation of CLL to DLBCL is challenging. For young fit patients, the standard of care remains RCHOP chemoimmunotherapy. Limited data exist exploring other options, including retrospective data sets and small prospective studies, but nothing published convincingl...
Sign in or Register to read more